This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Singer, D. R. Articles by MacGregor, G. A. Search for Related Content PubMed PubMed Citation Articles by Singer, D. R. Articles by MacGregor, G. A.

Hypertension, Vol 9, 629-633, Copyright © 1987 by American Heart Association

ARTICLES

Captopril and nifedipine in combination for moderate to severe essential hypertension

DR Singer, ND Markandu, AC Shore and GA MacGregor

The effects of the addition of a calcium entry antagonist, nifedipine (20-mg tablet twice a day), to an angiotensin converting enzyme inhibitor, captopril (25 mg three times a day), and the addition of captopril to nifedipine were observed in two separate studies in patients with essential hypertension. After 4 weeks of captopril therapy alone, mean arterial pressure fell by 12 mm Hg, and with the addition of nifedipine to captopril for a further month, blood pressure fell by an additional 10 mm Hg. In a separate group of patients treated with the same doses, mean arterial pressure fell by 17 mm Hg with nifedipine treatment alone; when captopril was added to the nifedipine therapy for an additional month, mean arterial pressure fell by a further 11 mm Hg. These blood pressures were measured 2 hours after the last dose; however, there was less of a fall in blood pressure when it was measured 12 hours after the last dose. This study confirms that captopril and nifedipine have a marked additive effect on blood pressure in whichever order they are given, but it shows that the combination is relatively short-acting.

This article has been cited by other articles:

				P. Swales and B. Williams Review: Calcium channel blockade in combination with angiotensin-converting enzyme inhibition or angiotensin II (AT1-receptor) antagonism in hypertensive diabetics and patients with renal disease and hypertension Journal of Renin-Angiotensin-Aldosterone System, June 1, 2002; 3(2): 79 - 89. [Abstract] [PDF]

				M U R Naidu, P R Usha, T R. K. Rao, and J C Shobha Evaluation of amlodipine, lisinopril, and a combination in the treatment of essential hypertension Postgrad. Med. J., June 1, 2000; 76(896): 350 - 353. [Abstract] [Full Text]

				M.R. Marino, J.L. Hammett, I. Ferreira, N.F. Ford, and H.D. Uderman Effect of Nifedipine on the Steady-State Pharmacokinetics and Pharmacodynamics of Irbesartan in Healthy Subjects Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1998; 3(2): 111 - 117. [Abstract] [PDF]

				M. Epstein and G. Bakris Newer Approaches to Antihypertensive Therapy: Use of Fixed-Dose Combination Therapy Arch Intern Med, September 23, 1996; 156(17): 1969 - 1978. [Abstract] [PDF]

				T. F. T. Antonios, F. P. Cappuccio, N. D. Markandu, G. A. Sagnella, and G. A. MacGregor A Diuretic Is More Effective Than a ß-Blocker in Hypertensive Patients Not Controlled on Amlodipine and Lisinopril Hypertension, June 1, 1996; 27(6): 1325 - 1328. [Abstract] [Full Text]